Long term effectiveness of low dose mithramycin for Paget's disease of bone.
Nineteen patients with Paget's disease of bone were studied 7 months to 5 years after therapy with mithramycin in a dose averaging 11.5 microgram/kg body weight daily for 10 days. Thirteen patients, including 3 with the longest followup intervals, remained free of pain. Objective measures of disease activity (serum alkaline phosphatase level and 99mtechnetium pyrophosphate bone scan) were less favorable. There was no evidence of long term toxicity.
D000368:Aged; D000469:Alkaline Phosphatase / Q000097:blood; D001842:Bone and Bones / Q000000981:diagnostic imaging; D004341:Drug Evaluation; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D010001:Osteitis Deformans / Q000175:diagnosis / Q000000981:diagnostic imaging / Q000188:drug therapy*; D008926:Plicamycin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011877:Radionuclide Imaging; D013997:Time Factors
D000469:Alkaline Phosphatase; D008926:Plicamycin